Cargando…
A novel standard to evaluate the impact of therapeutic agents on patient safety – The BURDEN OF THERAPY™(©∗)
PURPOSE: Currently, treatment-emergent adverse events (TEAEs) during a clinical study are summarized over the entire study period. OBJECTIVE: Develop and validate a novel methodology, BURDEN OF THERAPY(©∗) (BOTh(©∗)), to quantify presence and severity of TEAEs on each day of study. METHODS: BOTh uti...
Autores principales: | Abdulahad, Ayad K., Snijder, Robert J., Panni, Moeen K., Riaz, Faysal K., Karas, Andreas J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935900/ https://www.ncbi.nlm.nih.gov/pubmed/29736481 http://dx.doi.org/10.1016/j.conctc.2016.09.003 |
Ejemplares similares
-
Recent advances and future directions for the pharmacogenetic basis of anti-VEGF treatment response in neovascular age-related macular degeneration
por: Riaz, Moeen, et al.
Publicado: (2017) -
Book Reviews: Evaluating and Standardizing Therapeutic Agents, 1890–1950
por: Löwy, Ilana
Publicado: (2011) -
Agent-based model of the impact of higher influenza vaccine efficacy on seasonal influenza burden
por: Krauland, Mary G., et al.
Publicado: (2022) -
Ceritinib is a novel triple negative breast cancer therapeutic agent
por: Dong, Shengli, et al.
Publicado: (2022) -
Influence of tramadol on bacterial burden in the standard neutropenic thigh infection model
por: Rox, K.
Publicado: (2022)